Axsome Therapeutics Secures Sunosi Exclusivity Until 2040 with Patent Settlement
AXSM has more than doubled off its 52-week low of $96.09.
Summary
Axsome Therapeutics has successfully settled all patent litigation related to its drug Sunosi (solriamfetol). This agreement grants five generic companies the right to sell generic versions of Sunosi, but not until 2040, subject to FDA approval. The resolution removes a significant legal and commercial overhang, providing long-term clarity and protecting a key revenue stream for Axsome for over a decade. This positive development follows recent strong Q1 revenue growth and the FDA approval of AUVELITY for Alzheimer's agitation.
At the time of this announcement, AXSM was trading at $225.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4B. The 52-week trading range was $96.09 to $238.56. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.